secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-10-19T23:59:59+00:00
Accession:  0001070081-23-000056
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics monetizes Evrysdi royalties for up to $1.5B, pays off Blackstone debt
--------------------------------------------------------------------------------

- PTC receives $1.0B upfront for ~38% additional Evrysdi royalty; total ~81% sold to Royalty Pharma.
- PTC can sell remaining royalty for up to $500M via puts through Dec 2025; Royalty Pharma may call up to $250M.
- Proceeds to retire all Blackstone debt; Credit Agreement from Oct 2022 terminated.
- PTC retains all economics on up to $250M in commercial sales milestones for Evrysdi.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000056/0001070081-23-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000056/tmb-20231018x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-23-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer